Advertisement

Investigational New Drugs

, Volume 37, Issue 5, pp 810–817 | Cite as

The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer

  • Huijun Zhao
  • Juan Ma
  • Ting Lei
  • Wanru Ma
  • Man ZhangEmail author
PRECLINICAL STUDIES

Summary

Expression of CD155 differs between tumor and normal tissues, and high expression of this molecule can promote tumor metastasis. Here, we investigate whether CD155 can serve as a target for T cell-mediated immunotherapy of human prostate cancer. We first demonstrate that prostate cancer cells, including PC-3, PC-3 M, and LNCAP cells, express CD155 at high levels. Next, the specific cytotoxic activity of activated T cells (ATCs) armed with a novel anti-CD3 × anti-CD155 bispecific antibody (CD155Bi-Ab) against tumor cells was evaluated by flow cytometry, lactate dehydrogenase assay (LDH), and ELISA. In contrast to unarmed ATCs, an increase in the cytotoxic activity of CD155Bi-armed ATCs against tumor cells was observed at an effector/target (E/T) ratio of 5:1. Moreover, CD155Bi-armed ATCs secreted more IFN-γ, TNF-α, and IL-2 and expressed higher levels of the activation marker CD69 than did unarmed ATCs. As CD155 Bi-Ab enhances the ability of ATCs to kill prostate cancer cells, CD155 is an effective target for cytotoxic T cells in human prostate cancer therapy.

Keywords

Prostate cancer Immunotherapy CD155 Bispecific antibody 

Notes

Funding

The work was supported by the National Key R&D Plan (2016YFC1000702) and the Beijing Natural Science Foundation (7172106).

Compliance with ethical standards

Conflicts of interest

Huijun Zhao, Juan Ma, Ting Lei, Wanru Ma, Man Zhang declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. Ca-Cancer J Clin 68(1):7–30CrossRefGoogle Scholar
  2. 2.
    Tabayoyong W, Abouassaly R (2015) Prostate Cancer screening and the associated controversy. Surg Clin N Am 95(5):1023–1039CrossRefGoogle Scholar
  3. 3.
    Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19):3089–3094CrossRefGoogle Scholar
  4. 4.
    Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33–39CrossRefGoogle Scholar
  5. 5.
    Handy CE, Antonarakis ES (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14(10):907–917.  https://doi.org/10.2217/fon-2017-0531 CrossRefGoogle Scholar
  6. 6.
    Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, Investigators C (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700–712CrossRefGoogle Scholar
  7. 7.
    Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, Gasova Z, Klouckova J, Kayserova J, Horvath R, Fialova A, Vavrova K, Sochorova K, Rozkova D, Spisek R, Bartunkova J (2018) Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. Cancer Immunol Immunother 67(1):89–100CrossRefGoogle Scholar
  8. 8.
    Simons JW, Sacks N (2006) Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX (TM) vaccine for prostate cancer. Urol Oncol-Semin Ori 24(5):419–424CrossRefGoogle Scholar
  9. 9.
    Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG (2008) A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 57(2):155–163CrossRefGoogle Scholar
  10. 10.
    Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36(6):458–467CrossRefGoogle Scholar
  11. 11.
    Koike S, Horie H, Ise I, Okitsu A, Yoshida M, Iizuka N, Takeuchi K, Takegami T, Nomoto A (1990) The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J 9(10):3217–3224CrossRefGoogle Scholar
  12. 12.
    Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P, Denis MG (2001) Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49(2):236–240CrossRefGoogle Scholar
  13. 13.
    Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. P Natl Acad Sci USA 97(12):6803–6808CrossRefGoogle Scholar
  14. 14.
    Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI (1999) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163(1):507–513Google Scholar
  15. 15.
    Ma J, Ma P, Zhao CH, Xue X, Han HM, Liu CZ, Tao H, Xiu WG, Cai J, Zhang M (2016) B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget 7(20):29480–29491Google Scholar
  16. 16.
    Han HM, Ma J, Zhang KM, Li W, Liu CZ, Zhang Y, Zhang GL, Ma P, Wang L, Zhang G, Tao H, Gao B (2014) Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. Int J Oncol 45(6):2446–2454CrossRefGoogle Scholar
  17. 17.
    Ma J, Han HM, Liu DR, Li W, Feng HX, Xue X, Wu XR, Niu G, Zhang G, Zhao YF, Liu CZ, Tao H, Gao B (2013) HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One 8(8):e73261Google Scholar
  18. 18.
    Paulus H (1985) Preparation and biomedical applications of bispecific antibodies. Behring Inst Mitt 78:118–132Google Scholar
  19. 19.
    Sebastian M (2010) Review of catumaxomab in the treatment of malignant ascites. Cancer Manag Res 2:283–286.  https://doi.org/10.2147/CMR.S14115 CrossRefGoogle Scholar
  20. 20.
    Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 31(9):871–884.  https://doi.org/10.1097/CJI.0b013e318186c8b4 CrossRefGoogle Scholar
  21. 21.
    Lum LG, Davol PA (2005) Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother Biol Response Modif 22:273–291CrossRefGoogle Scholar
  22. 22.
    Mendelsohn CL, Wimmer E, Racaniello VR (1989) Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56(5):855–865CrossRefGoogle Scholar
  23. 23.
    Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198(4):557–567CrossRefGoogle Scholar
  24. 24.
    Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6(1):56–68.  https://doi.org/10.1038/nrm1549 CrossRefGoogle Scholar
  25. 25.
    Ochiai H, Moore SA, Archer GE, Okamura T, Chewning TA, Marks JR, Sampson JH, Gromeier M (2004) Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 10(14):4831–4838.  https://doi.org/10.1158/1078-0432.CCR-03-0694 CrossRefGoogle Scholar
  26. 26.
    Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG (2005) CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 65(23):10930–10937.  https://doi.org/10.1158/0008-5472.CAN-05-1890 CrossRefGoogle Scholar
  27. 27.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsasser-Beile U (2000) Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res 20(3A):1551–1555Google Scholar
  28. 28.
    Stein ID (1970) Serum lactate dehydrogenase isoenzymes: stability, clearance, and diagnostic application in hemolytic anemia. J Lab Clin Med 76(1):76–84Google Scholar
  29. 29.
    Vanderlinde RE (1985) Measurement of total lactate dehydrogenase activity. Ann Clin Lab Sci 15(1):13–31Google Scholar
  30. 30.
    Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JJ, Bickham KL, Lerner H, Goldstein M, Sykes M, Kato T, Farber DL (2013) Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 38(1):187–197.  https://doi.org/10.1016/j.immuni.2012.09.020 CrossRefGoogle Scholar
  31. 31.
    Cibrian D, Sanchez-Madrid F (2017) CD69: from activation marker to metabolic gatekeeper. Eur J Immunol 47(6):946–953.  https://doi.org/10.1002/eji.201646837 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Huijun Zhao
    • 1
    • 2
  • Juan Ma
    • 1
    • 2
  • Ting Lei
    • 1
    • 2
    • 3
  • Wanru Ma
    • 2
  • Man Zhang
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Clinical Laboratory, Beijing Shijitan HospitalCapital Medical UniversityBeijingChina
  2. 2.Beijing Key Laboratory of Urinary Cellular Molecular DiagnosticsBeijingChina
  3. 3.Department of Clinical LaboratoryPeking University Ninth School of Clinical MedicineBeijingChina

Personalised recommendations